Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
0.6319
+0.0106 (1.71%)
At close: Mar 6, 2026, 4:00 PM EST
0.6300
-0.0019 (-0.30%)
After-hours: Mar 6, 2026, 6:46 PM EST
Revenue by Segment
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
|---|
Discovery and Development of Cancer Therapeutics | 1.89M | 19.94M | 16.40M | - | - | |
Discovery and Development of Cancer Therapeutics Growth | -90.55% | 21.60% | - | - | - | |
| 1.89M | 19.94M | 16.40M | - | - | |
| -90.55% | 21.60% | - | - | - | |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
|---|
| 1.89M | 19.94M | 16.40M | - | - | |
| -90.55% | 21.60% | - | - | - | |
| 1.89M | 19.94M | 16.40M | - | - | |
| -90.55% | 21.60% | - | - | - | |
Source: S&P Global Market Intelligence.
